THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview

被引:171
作者
Alexander, Stephen P. H. [1 ]
Kelly, Eamonn [2 ]
Marrion, Neil V. [2 ]
Peters, John A. [3 ,4 ]
Faccenda, Elena [5 ]
Harding, Simon D. [5 ]
Pawson, Adam J. [5 ]
Sharman, Joanna L. [5 ]
Southan, Christopher [5 ]
Buneman, O. Peter [6 ]
Cidlowski, John A. [7 ]
Christopoulos, Arthur [8 ,9 ]
Davenport, Anthony P. [10 ]
Fabbro, Doriano [11 ]
Spedding, Michael [12 ]
Striessnig, Jorg [13 ]
Davies, Jamie A. [5 ]
Abbracchio, M. P.
Aldrich, R.
Al-Hosaini, K.
Arumugam, T., V
Attali, B.
Back, M.
Barnes, N. M.
Bathgate, R.
Beart, P. M.
Becirovic, E.
Bettler, B.
Biel, M.
Birdsall, N. J.
Blaho, V
Boison, D.
Brauner-Osborne, H.
Broer, S.
Bryant, C.
Burnstock, G.
Calo, G.
Catterall, W. A.
Ceruti, S.
Chan, S. L.
Chandy, K. G.
Chazot, P.
Chiang, N.
Chun, J. J.
Chung, J. J.
Clapham, D. E.
Clapp, L.
Connor, M. A.
Cox, H. M.
Davies, P.
机构
[1] Univ Nottingham, Sch Life Sci, Sch Med, Nottingham NG7 2UH, England
[2] Univ Bristol, Sch Physiol Pharmacol & Neurosci, Bristol BS8 1TD, Avon, England
[3] Univ Dundee, Ninewells Hosp, Med Educ Inst, Neurosci Div, Dundee DD1 9SY, Scotland
[4] Univ Dundee, Sch Med, Dundee DD1 9SY, Scotland
[5] Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland
[6] Univ Edinburgh, Sch Informat, Lab Foundat Comp Sci, Edinburgh EH8 9LE, Midlothian, Scotland
[7] NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA
[8] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia
[9] Monash Univ, Dept Pharmacol, Parkville, Vic 3052, Australia
[10] Univ Cambridge, Clin Pharmacol Unit, Cambridge CB2 0QQ, England
[11] PIQUR Therapeut, CH-4057 Basel, Switzerland
[12] Spedding Res Solut SARL, F-78110 Le Vesinet, France
[13] Univ Innsbruck, Inst Pharm, Pharmacol & Toxicol, A-6020 Innsbruck, Austria
基金
英国惠康基金; 英国工程与自然科学研究理事会;
关键词
D O I
10.1111/bph.13882
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Concise Guide to PHARMACOLOGY 2017/18 is the third in this series of biennial publications. This version provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13882/full. In addition to this overview, in which are identified 'Other protein targets' which fall outside of the subsequent categorisation, there are eight areas of focus: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
引用
收藏
页码:S1 / S16
页数:16
相关论文
共 6 条
[1]  
Carven GJ, 2010, Antibodies to human programmed death receptor PD-1, Patent No. [US20100266617, 20100266617]
[2]  
Halk EL, 2001, Human ctla-4 antibodies and their uses, Patent No. [2001014424, WO2001014424]
[3]  
Hanson DC, 2004, Human monoclonal antibodies to CTLA-4, Patent No. [US6682736 B1, 6682736]
[4]  
Korman A, 2006, Human monoclonal anti-bodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics, Patent No. [WO2006/121168A1, 2006121168, WO 2006121168]
[5]  
Liu Q, 2013, Fully human antibodies against human cd20, Patent No. [WO2013007052, 2013007052]
[6]  
Shitara K, 2011, [No title captured], Patent No. [US7923538 B2, 7923538]